• Home
  • NEW DAY MEDICINE
  • 11 (73) 2024
  • 3 -11 (73) 2024 - Kendzhaeva K.Sh., Khaidarova F.A. - DYNAMICS OF SYMPTOMS OF DIABETIC POLYNEUROPATHY DUE TO COMPLETION OF VITAMIN B12 DEFICIENCY

3 -11 (73) 2024 - Kendzhaeva K.Sh., Khaidarova F.A. - DYNAMICS OF SYMPTOMS OF DIABETIC POLYNEUROPATHY DUE TO COMPLETION OF VITAMIN B12 DEFICIENCY

DYNAMICS OF SYMPTOMS OF DIABETIC POLYNEUROPATHY DUE TO COMPLETION OF VITAMIN B12 DEFICIENCY

Kendzhaeva K.Sh. - Republican Specialized Scientific and Practical Medical Center of Endocrinology named after Academician Y. Kh. Turakulov, Specialized Hospital

Khaidarova F.A. - Republican Specialized Scientific and Practical Medical Center of Endocrinology named after Academician Y. Kh. Turakulov, Specialized Hospital

Resume

Vitamin B12 (cobalamin) plays a key role in cell metabolism and nervous system maintenance. Vitamin B12 deficiency can lead to various neurological disorders, including polyneuropathy. Polyneuropathy caused by vitamin B12 deficiency can mimic diabetic polyneuropathy, making diagnosis and treatment difficult. Polyneuropathy caused by vitamin B12 deficiency can mimic diabetic polyneuropathy, making diagnosis and treatment difficult. This article presents the results of changes in the symptoms of diabetic polyneuropathy against the background of replenishing vitamin B12 deficiency. The best results were obtained in terms of improving vibration sensitivity, reducing the frequency of complaints of pain and numbness of the lower extremities.

Key words: dynamics of symptoms of diabetic polyneuropathy, replenishment of vitamin B12 deficiency, cell metabolism and maintenance of the nervous system.

First page

13

Last page

18

For citation:Kendzhaeva K.Sh., Khaidarova F.A. - DYNAMICS OF SYMPTOMS OF DIABETIC POLYNEUROPATHY DUE TO COMPLETION OF VITAMIN B12 DEFICIENCY//New Day in Medicine 11(73)2024 13-18 https://https://newdayworldmedicine.com/en/new_day_medicine/11-73-2024

List of References

  1. IDF (Electronic resource). URL: http://www.diabetesatlas.org/ (access date: 22.02.2020).
  2. Дедов И.И., Шестакова М.В. Персонализированная терапия сахарного диабета: путь от болезни к больному. Терапевтический архив. 2014;86(10):4-9. [Dedov I.I., Shestakova M.V. Personalized therapy of diabetes mellitus: the path from illness to sick. Therapeutic archive. 2014;86(10):4-9 (in Russ.)].
  3. Volmer-Thole M., Lobmann R. Neuropathy and Diabetic Foot Syndrome. Int J Mol Sci. 2016;17(6):917. DOI: 10.3390/ijms17060917.
  4. Said G. Diabetic neuropathy. Handbook Clin. Neurol. 2013;115:579–589.
  5. Ziegler D., Keller J., Maier C., Pannek J. Diabetic neuropathy. Exp. Clin. Endocrinol. Diabet Off J Ger Soc. Endocrinol Ge Diabet. Assoc. 2014;122:406-415. DOI:10.1055/s-0034-1366435.e
  6. Stino A.M., Smith A.G. Peripheral neuropathy in prediabetes and the metabolic syndrome. J Diabetes Investig. 2017;8(5):646-655. DOI: 10.1111/jdi.12650.
  7. Дедов И.И., Шестакова М.В., Галстян Г.Р. Распространенность сахарного диабета 2 типа у взрослого населения России (исследование NATION). Сахарный диабет. 2016;19(2):104-112.
  8. Russell J.W., Zilliox L.A. Diabetic neuropathies. Continuum. 2014;20:1226-1240. DOI: 10.1212/01.CON.0000455884.29545.d2.
  9. Boulton A.J. The pathway to foot ulceration in diabetes. Med Clin North Am. 2013;97(5):775-790. DOI: 10.1016/j.mcna.2013.03.007.
  10. Зиновьева О.Е., Казанцева Ю.Ф. Патогенетическая терапия дисметаболических полиневропатий. Трудный пациент. 2011;7:38-45. [Zinoviev O.E., Kazantseva Yu.F. Pathogenetic therapy of dysmetabolic polyneuropathies. Difficult Patient. 2011;7:38-45 (in Russ.)].
  11. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54(6):1615-1625. DOI: 10.2337/diabetes.54.6.1615.
  12. Sandireddy R., Yerra V.G., Areti A., Komirishetty P., Kumar A. Neuroinflammation and oxidative stress in diabetic neuropathy: Futuristic strategies based on these targets. Int. J. Endocrinol. 2014:674-987. DOI: 10.1155/2014/674987.
  13. Thornalley P.J., Babaei-Jadidi R., Al Ali H. et al. High prevalence of low plasma thiamine concentration in diabetes linked to a marker of vascular disease. Diabetologia. 2007;50(10):164-2170.
  14. Zenker J., Ziegler D., Chrast R. Novel pathogenic pathways in diabetic neuropathy. Trends Neurosci. 2013;36:439-449. DOI: 10.1016/j.tins.
  15. Singh V.P., Bali A., Singh N., Jaggi A.S. Advanced glycation end products and diabetic complications. Korean J. Physiol. Pharmacol. 2014;18:1–14. DOI:10.4196/kjpp.
  16. Заводник И.Б., Дремза И.К., Лапшина Е.А., Чещевик В.Т. Сахарный диабет: метаболические эффекты и окислительный стресс. Биологические мембраны. 2011;28(2):83-94. [Zavodnik I.B., Dremza I.K., Lapshina E.A., Cheshevik V.T. Diabetes mellitus: metabolic effects and oxidative stress. Biological membranes. 2011;28(2):83-94 (in Russ.)].
  17. Садырин А.В., Карпова М.И., Долганов М.В. Диабетическая полинейропатия: вопросы патогенеза и возможности лечения. РМЖ. 2016;1:47-50. [Sadyrin A.V., Karpova M.I., Dolganov M.V. Diabetic polyneuropathy: issues of pathogenesis and treatment options. RMJ. 2016;1:47-50 (in Russ.)].
  18. Dyck P.J., Albers J.W., Andersen H. et al. Toronto Expert Panel on Diabetic Neuropathy. Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. Diabetes Metab Res Rev. 2011;27(7):620-628.
  19. Нечаева Г.И., Друк И.В., Лялюкова А.С., Кореннова А.Ю. Современное понимание клинического значения гипергомоцистеинемии: акцент на сахарный диабет. Лечащий врач. 2017;9:58-65. [Nechaeva G.I., Druk I.V., Lyalyukova A.S., Korennova A.Yu. A modern understanding of the clinical significance of hyperhomocysteinemia: an emphasis on diabetes. The attending physician. 2017; 9:58-65 (in Russ.)].
  20. Sugimoto K., Murakawa Y., Sima A.A. Diabetic neuropathy - a continuing enigma. Diabetes Metab Res Rev. 2000;16(6):408-433.

    file

    download